- Home
- KNOP vs ALDX Comparison
KNOP vs ALDX Comparison
Compare KNOP & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | ALDX |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.6M | 293.0M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KNOP | ALDX |
|---|---|---|
| Price | $10.74 | $4.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 141.2K | ★ 953.0K |
| Earning Date | 12-04-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $352,712,000.00 | N/A |
| Revenue This Year | $13.56 | N/A |
| Revenue Next Year | $2.42 | $36.25 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $5.28 | $1.14 |
| 52 Week High | $10.99 | $7.20 |
Technical Indicators
Market Signals| Indicator | KNOP | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 66.95 | 39.04 |
| Support Level | $10.41 | $4.67 |
| Resistance Level | $10.85 | $5.04 |
| Average True Range (ATR) | 0.22 | 0.29 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 79.57 | 3.42 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.